Therapy Area topics

Cardiovascular

Central Nervous System

Vantage logo

Esketamine floats past adcom vote

Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.

Diabetes

Digital Health

Oncology

Respiratory

Various

Vantage logo

Orphazyme tries its luck 

Despite missing pretty much all the endpoints of a registrational study, the Danish company insists that it has a chance of approval for a treatment for an incurable…

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.